Creating a cosmetic line from scratch: the 2026 guide

This guide analyzes the strategic nodes of the industrial development journey, providing the essential technical parameters to set up a sustainable business plan in the B2B and B2C sectors.

If you are considering launching your own line or already have a project in the pipeline, understanding these dynamics is the first step to avoid making fatal errors during the strategic planning phase.

Business Architecture and R&D (Research and Development)

The R&D phase determines the fixed and variable cost structure of the operation. Before interfacing with a laboratory, it is necessary to define the product's industrial framework. The choice of manufacturing model directly impacts Time-to-Market (TTM) and the initial financial requirement.

The White Label model is predominantly based on catalog formulas. In this case, the contract manufacturer most likely already owns the intellectual property of the formula, the stability tests, and the raw materials dossier. The start-up solely customizes the secondary packaging and the graphic design of the primary packaging. This approach guarantees a reduced initial investment, low MOQs (Minimum Order Quantities) which often stand between 200 and 500 pieces per SKU, and a time-to-market of less than three months. The main disadvantage lies in the total absence of chemical differentiation and high vulnerability to price competition.

The Private Label model with adaptation represents a semi-custom solution. It starts from a manufacturer's existing formulation base and requires the insertion of a specific active ingredient or a change in fragrance, requiring new partial stability tests.

The Custom Formulation, on the other hand, consists of pure contract manufacturing, meaning the development of a proprietary formula ex novo. This guarantees exclusivity of the formula and exact compliance with a precise technical brief, but entails high R&D costs, minimum industrial MOQs generally starting from 3,000 or 5,000 units per SKU, and development times of no less than six to nine months. Passing the sampling sessions requires a technical brief free of qualitative ambiguities.

The document must specify the industrial target price, understood as the maximum tolerable cost per kilogram of bulk (unpackaged product) or per finished unit inclusive of filling. It must also define the chemical-physical specifications such as the desired viscosity, target pH, and restrictions on specific ingredient classes, for example the absence of non-biodegradable synthetic polymers. Finally, it is necessary to indicate the objective claims intended to be featured on the label, such as 24-hour hydration, which will guide the choice of active ingredients and subsequent in vivo or in vitro efficacy tests; these are not mandatory but better support the claim.

Compliance d'impatto: il Regolamento CE n. 1223/2009

L'immissione in commercio di un cosmetico in Europa non prevede un'autorizzazione preventiva, ma si basa sul principio di auto-responsabilizzazione del produttore e del brand. L'errore normativo comporta il sequestro dei lotti e sanzioni penali o amministrative gravose.

La Persona Responsabile è il soggetto, giuridico o fisico, stabilito nella Comunità Europea che garantisce la conformità di ogni singolo lotto immesso sul mercato. La Persona Responsabile risponde legalmente di fronte alle autorità competenti, come il Ministero della Salute e i NAS. Se la start-up esternalizza la produzione ma commercializza a proprio nome, assume di default questo ruolo, a meno che non contrattualizzi un consulente terzo specializzato per assumere tale veste.

Il Product Information File, noto come PIF, è un dossier tecnico dinamico che deve essere conservato per dieci anni dall'immissione sul mercato dell'ultimo lotto. Al suo interno risiede la descrizione del prodotto cosmetico utile alla sua identificazione univoca per legare il dossier al prodotto commerciale. Comprende poi la Relazione sulla Sicurezza del Prodotto Cosmetico, redatta da un tossicologo qualificato e divisa in Parte A, relativa alle informazioni sulla sicurezza, e Parte B, riguardante la valutazione della sicurezza stessa. Il dossier integra inoltre la descrizione del metodo di fabbricazione con la dichiarazione di conformità alle linee guida ISO 22716 per le buone pratiche di fabbricazione, le prove degli effetti attribuiti a supporto dei claim pubblicitari, e i dati sulle sperimentazioni animali che attestano l'assenza di test, vietati in Unione Europea dal 2013 anche per le materie prime.

L'approvazione del dossier è subordinata al superamento di un pannello di test di validazione obbligatori. Il Challenge Test, regolato dalla norma ISO 11930, prevede l'inoculazione artificiale di ceppi batterici e fungini nel bulk per verificare la capacità del sistema conservante di neutralizzare la contaminazione durante l'uso. I test di Stabilità e Compatibilità, eseguiti in tempo reale e in modalità accelerata, monitorano il prodotto a temperature variabili, solitamente a quattro, venti e quaranta gradi centigradi, per simulare l'invecchiamento in trentasei mesi. Questo processo verifica l'assenza di sineresi, variazioni di colore, alterazioni del pH e la mancata interazione chimica con i materiali del packaging primario, escludendo fenomeni di migrazione di sostanze non intenzionalmente aggiunte.

Impact Compliance: EC Regulation No. 1223/2009

The placing on the market of a cosmetic product in Europe does not require prior authorization, but is based on the principle of self-responsibility of the manufacturer and the brand. Regulatory error leads to the seizure of batches and heavy criminal or administrative sanctions.

The Responsible Person is the legal or natural person established within the European Community who guarantees the compliance of every single batch placed on the market. The Responsible Person is legally accountable to the competent authorities, such as the Ministry of Health and health protection units (NAS). If the start-up outsources production but markets under its own name, it assumes this role by default, unless it contracts a specialized third-party consultant to take on this capacity.

The Product Information File, known as PIF, is a dynamic technical dossier that must be kept for ten years from the placing on the market of the last batch. Inside it lies the description of the cosmetic product useful for its unique identification to link the dossier to the commercial product. It then includes the Cosmetic Product Safety Report, drafted by a qualified toxicologist and divided into Part A, relating to safety information, and Part B, concerning the safety assessment itself.

The dossier also integrates the description of the manufacturing method with the declaration of compliance with the ISO 22716 guidelines for Good Manufacturing Practices, proof of the effects attributed to support advertising claims, and data on animal testing certifying the absence of tests, banned in the European Union since 2013 even for raw materials.

The approval of the dossier is subject to passing a panel of mandatory validation tests. The Challenge Test, regulated by the ISO 11930 standard, involves the artificial inoculation of bacterial and fungal strains into the bulk to verify the ability of the preservative system to neutralize contamination during use. Stability and Compatibility tests, performed in real time and accelerated mode, monitor the product at variable temperatures, usually at four, twenty, and forty degrees Celsius, to simulate aging over thirty-six months. This process verifies the absence of syneresis, color variations, pH alterations, and the lack of chemical interaction with the primary packaging materials, excluding migration phenomena of substances not intentionally added.

Industrial Supply Chain: Packaging and Production

The optimization of the gross margin depends on the alignment of lead times between raw material suppliers, packaging suppliers, and the contract manufacturer. Primary packaging must meet industrial compatibility criteria before aesthetic requirements. Airless bottles protect oxidizable formulas, such as unstable Vitamin C or retinoids, by reducing exposure to air and minimizing the use of heavy antioxidants.

The choice between glass and technical polymers highlights opposite structural dynamics, as glass guarantees total chemical inertness but increases logistics costs related to weight and breakage risks on automatic filling lines. Conversely, recycled plastics require specific compatibility tests due to the potential presence of recycling contaminants.

Moving from the laboratory beaker to the industrial turbo-emulsifier involves an inherent risk of variation in the product's rheological structure. For this reason, the contract manufacturer must run a pilot batch, usually equal to ten percent of the final batch volume, to accurately calibrate the agitation, shear, and cooling parameters of the mass prior to final production. Finding a manufacturer capable of managing this transition without altering the bulk is one of the most critical decisions in the process.

Precisely in this operational phase, the mapping of contract manufacturers becomes a strategic asset. Specialized B2B platforms like Cosmetitrovo step in exactly here, simplifying the search and connecting your project with the most suitable industrial laboratories and packaging suppliers in terms of production capacity, certifications, and MOQs.

The Financial Node: The Cash Flow Trap in B2B

The failure of cosmetic start-ups is rarely caused by incorrect formulas. The real cause is almost always a liquidity crisis due to underestimating the working capital cycle. In the cosmetics market, cash inflows and outflows travel at dangerously asymmetrical speeds. Imagine this scenario: you receive a major order from a pharmacy chain or a perfume distributor. It is the breakthrough moment, but there is an invisible obstacle.

The contract manufacturing laboratory and the packaging supplier demand payment of industrial costs under rigid terms, such as fifty percent upon order and fifty percent upon delivery of the finished batch. The pharmacy chain, on the other hand, will pay your invoice at sixty, ninety, or even one hundred and twenty days from the delivery of the goods. This means that your start-up must finance the entire production, packaging, laboratory tests, and logistics months before collecting the first euro from the final customer.

Without millimeter-precise financial planning, a large order can paradoxically drain your cash reserves and freeze the company right at the moment of growth. In calculating price positioning, it is essential to consider the industrial cost multipliers required by the distribution chain to absorb these payment deferrals. A finished production cost equal to three euros generally requires a multiplier of four or five times to define the B2B selling price to the retailer, who in turn applies a margin of between fifty and sixty percent to determine the final retail price net of VAT. The pharmacy and parapharmacy channel requires heavy investments in sell-out, which include training counter staff, providing samples, and display materials, guaranteeing constant volumes against long payment terms.

The beauty salon and spa channel requires the development of specific cabin treatments and large professional sizes, offering high margins for the brand but a slower market penetration linked to the capillarity of the agent network. The direct-to-consumer e-commerce model eliminates the commercial middleman, but shifts the entire financial cost onto the customer acquisition cost through performance marketing platforms. To mitigate this heavy initial financial exposure and cover R&D, regulatory, and initial batch purchase costs, it becomes essential to integrate subsidized finance tools into the business plan. Through incentive programs managed by Invitalia or regional grants funded by the European Regional Development Fund, new enterprises, particularly those focused on female or youth entrepreneurship or sustainable innovation, can access a mix of zero-interest loans and non-repayable grants capable of covering up to eighty percent of eligible expenses. These funds represent the oxygen needed to overcome the payment misalignment between industrial production and commercial channels.

Regulatory and Institutional References

The drafting of the business plan and the safety dossier must refer to EC Regulation No. 1223/2009, which constitutes the framework regulation of the European Parliament and of the Council on cosmetic products. Manufacturing processes must be validated according to the UNI EN ISO 22716 standard, which defines the guidelines for Good Manufacturing Practices for cosmetic products. For the toxicological assessment of ingredients and the determination of safety margins, the European reference body is the Scientific Committee on Consumer Safety (SCCS), through its official notes of guidance.